VP

Vertex Pharmaceuticals Incorporated

Every trial this sponsor leads in the registry, and everything it has published.

260All trials
Recruiting13
Recruited13
Not yet recruiting3
By invitation3
Completed202
Stopped25
Other1

32 active · 12% of this sponsor’s registry footprint

Respiratory9 trials
Metabolic/Endocrine/Nutrition7 trials
Renal & Urology6 trials
Haematology4 trials
Neurology2 trials
Immunology & Inflammation1 trial
Pain & Musculoskeletal1 trial

Not shown above: 2 trials whose condition matched no therapy area.

Trials by phase

Phase 1102
Phase 270
Phase 381
Phase 46
Unphased1

Pipeline by phase · 15 drugs in active development

Phase 3 · 5 drugs

Povetacicept5 trials · 2 recruitingest. Jan 2028
Exagamglogene Autotemcel (CTX001)4 trials · 1 recruitingest. Jun 2027
VNZ/TEZ/D-IVA3 trialsest. Oct 2026
ELX/TEZ/IVA2 trialsest. Apr 2027
Zimislecel (VX-880)2 trials · 2 recruitingest. Sept 2026

Phase 2 · 4 drugs

VX-4072 trialsest. Mar 2027
VX-6702 trialsest. Feb 2027
Inaxaplin (VX-147)1 trial · 1 recruitingest. Jun 2028
VX-9931 trial · 1 recruitingest. Mar 2027

Phase 1 · 5 drugs

VX-5812 trials · 1 recruitingest. Oct 2026
VX-2641 trialest. Mar 2027
VX-2721 trial · 1 recruitingest. Mar 2027
VX-4331 trial · 1 recruitingest. Mar 2027

Phase 4 · 1 drug

Suzetrigine4 trials · 3 recruitingest. Jan 2027

Active trials only, code names and brands merged. 202 completed trials are in the counts above but their drugs are not folded into this pipeline.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon